Study Evaluating the Efficacy of DVS-233 in Fibromyalgia

Phase 3TerminatedNCT00301431

Wyeth is now a wholly owned subsidiary of Pfizer1,050 enrolled

Overview

The purpose of this study is to determine if DVS-233 is safe and effective in the treatment of pain and other symptoms of fibromyalgia syndrome.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

1,050

Conditions

Fibromyalgia

Interventions

DVS-233DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Fibromyalgia according to 1990 American College of Rheumatology (ACR) criteria Exclusion Criteria: * Other painful conditions that may make results difficult to interpret. * Treatment with other drugs for fibromyalgia with 14 days of study start or during the study.

Locations (59)

Outcomes

Primary Outcomes

The primary outcome will be the change in the daily pain score from baseline to study day 105 of therapy.

Secondary Outcomes

Fibromyalgia Impact Questionnaire and the Patient Global Impression of Change

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Huntsville, Alabama, United States

Unnamed facility

Mobile, Alabama, United States

Unnamed facility

Phoenix, Arizona, United States

Unnamed facility

Anaheim, California, United States

Unnamed facility

Sacramento, California, United States

Unnamed facility

San Diego, California, United States

Unnamed facility

Santa Ana, California, United States

Unnamed facility

Walnut Creek, California, United States

Unnamed facility

Denver, Colorado, United States

Unnamed facility

Cromwell, Connecticut, United States

...and 49 more locations